Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 5th edition, 486 pages

Free download

  Gastric Cancer

  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 200 articles:
HTML format

Single Articles

    November 2020
  1. TRUMBULL D, Lemini R, Attwood K, Kukar M, et al
    Gastric Cancer Disparities Among Asian American Subpopulations.
    Anticancer Res. 2020;40:6381-6385.
    PubMed     Abstract available

  2. CHEN YC, Wu CC, Tu YT, Chen YR, et al
    Involvement of the MicroRNA-1-LITAF Axis in Gastric Cancer Cell Growth and Invasion.
    Anticancer Res. 2020;40:6247-6256.
    PubMed     Abstract available

  3. MAKI M, SOderstrOm D, Paloheimo L, Hendolin P, et al
    Helicobacter pylori (Hp) IgG ELISA of the New-Generation GastroPanel(R) Is Highly Accurate in Diagnosis of Hp-Infection in Gastroscopy Referral Patients.
    Anticancer Res. 2020;40:6387-6398.
    PubMed     Abstract available

    October 2020
  4. HASHIMOTO I, Oue N, Kimura Y, Hiroshima Y, et al
    Clinical Significance of Glioma-associated Oncogene 1 Expression in Patients With Locally Advanced Gastric Cancer Administered Adjuvant Chemotherapy With S-1 After Curative Surgery.
    Anticancer Res. 2020;40:5815-5821.
    PubMed     Abstract available

  5. ENDO S, Fujiwara Y, Yamatsuji T, Nishikawa K, et al
    Is it Necessary to Confirm Negative Margins in Gastrectomy for Peritoneal Lavage Cytology-positive Gastric Cancer?
    Anticancer Res. 2020;40:5807-5813.
    PubMed     Abstract available

  6. UEJIMA C, Morimoto M, Yamamoto M, Hara K, et al
    Prognostic Significance of TYRO3 Receptor Tyrosine Kinase Expression in Gastric Cancer.
    Anticancer Res. 2020;40:5593-5600.
    PubMed     Abstract available

  7. SUGISAWA N, Nishino H, Higuchi T, Park JH, et al
    A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy.
    Anticancer Res. 2020;40:5393-5397.
    PubMed     Abstract available

    August 2020
  8. KIM EY, Jun KH, Yim K
    The Roles of Connexin 26, 32, and 43 as Prognostic Factors for Gastric Cancer.
    Anticancer Res. 2020;40:4537-4545.
    PubMed     Abstract available

  9. KANAZAWA Y, Yamada T, Kakinuma D, Matsuno K, et al
    Skeletal Muscle Mass Depletion After Gastrectomy Negatively Affects the Prognosis of Patients With Gastric Cancer.
    Anticancer Res. 2020;40:4271-4279.
    PubMed     Abstract available

    July 2020
  10. MAEZAWA Y, Aoyama T, Ju M, Komori K, et al
    The Impact of Severe Infectious Complications on Long-term Prognosis for Gastric Cancer.
    Anticancer Res. 2020;40:4067-4074.
    PubMed     Abstract available

    June 2020
  11. KIM DS, Min K, Lee SK
    Cell Cycle Dysregulation Is Associated With 5-Fluorouracil Resistance in Gastric Cancer Cells.
    Anticancer Res. 2020;40:3247-3254.
    PubMed     Abstract available

  12. YANG JW, Lee JH, Lee JS, Kim DC, et al
    Characteristics of Gastric Carcinomas With High ERCC1 Expression and the Prognostic Value of ERCC1 Expression.
    Anticancer Res. 2020;40:3203-3208.
    PubMed     Abstract available

  13. KUBOTA T, Shoda K, Ogawa S, Matsumoto T, et al
    Oncological Safety of Ultrasonically Activated Surgical Devices During Gastric Cancer Surgery.
    Anticancer Res. 2020;40:3163-3167.
    PubMed     Abstract available

  14. DI GIROLAMO M, Carbonetti F, Bonome P, Grossi A, et al
    Hydro-MDCT for Gastric Adenocarcinoma Staging. A Comparative Study With Surgical and Histopathological Findings for Selecting Patients for Echo-endoscopy.
    Anticancer Res. 2020;40:3401-3410.
    PubMed     Abstract available

  15. TUNG KL, Wu YT, Liu C, Lin SC, et al
    EBV Rta-induced IL-6 Promotes Migration of Bystander Tumor Cells Through IL-6R/JAK/STAT3 Pathway In Vitro.
    Anticancer Res. 2020;40:3255-3264.
    PubMed     Abstract available

    May 2020
  16. ILLUMINATI G, Pasqua R, Nardi P, Fratini C, et al
    Resection for Internal Jugular Vein Thrombosis and Cervical Lymph Nodes' Involvement from Gastric Cancer.
    Anticancer Res. 2020;40:2889-2893.
    PubMed     Abstract available

    April 2020
  17. ENDO S, Ikenaga M, Yamada T, Tamura S, et al
    Prognostic Factors for Para-aortic Lymph Node Dissection After Neoadjuvant Chemotherapy for Gastric Cancer.
    Anticancer Res. 2020;40:2351-2357.
    PubMed     Abstract available

  18. KATO K, Narita Y, Mitani S, Honda K, et al
    Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer.
    Anticancer Res. 2020;40:2247-2255.
    PubMed     Abstract available

  19. BRAEUER F, Fischer I, Brammen L, Pressl G, et al
    Outcome in Patients Treated With Cytoreductive Surgery and HIPEC for Gastric Cancer With Peritoneal Carcinomatosis.
    Anticancer Res. 2020;40:2151-2156.
    PubMed     Abstract available

  20. KIM HB, Lee HJ, Kim GB, Lim HJ, et al
    Clinical Significance of Jagged-1 Activated by APEX1 as a Chemoresistance Factor in Advanced Gastric Cancer.
    Anticancer Res. 2020;40:1897-1904.
    PubMed     Abstract available

  21. SHIMODA Y, Yamada T, Komori K, Watanabe H, et al
    Effect of Muscle Mass Loss After Esophagectomy on Prognosis of Oesophageal Cancer.
    Anticancer Res. 2020;40:2275-2281.
    PubMed     Abstract available

    March 2020
  22. VIRGILIO E, Proietti A, D'Urso R, Cardelli P, et al
    Elevated Gastric Juice Carbohydrate Antigen 72.4 (Ca 72.4) Is an Independent Prognostic Factor of Poor Survival for Gastric Cancer Patients.
    Anticancer Res. 2020;40:1691-1695.
    PubMed     Abstract available

  23. WATANABE H, Hayashi T, Komori K, Hara K, et al
    Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1.
    Anticancer Res. 2020;40:1683-1690.
    PubMed     Abstract available

  24. HARA K, Aoyama T, Yamada T, Nakazono M, et al
    The Prognostic Value of the Perioperative Systemic Inflammation Score for Patients With Advanced Gastric Cancer.
    Anticancer Res. 2020;40:1503-1512.
    PubMed     Abstract available

  25. MIGITA K, Matsumoto S, Wakatsuki K, Kunishige T, et al
    RNF126 as a Marker of Prognosis and Proliferation of Gastric Cancer.
    Anticancer Res. 2020;40:1367-1374.
    PubMed     Abstract available

    February 2020
  26. SAWASAKI M, Tsubamoto H, Nakamoto Y, Kakuno A, et al
    S-1, Oxaliplatin, Nab-paclitaxel and Itraconazole for Conversion Surgery for Advanced or Recurrent Gastric Cancer.
    Anticancer Res. 2020;40:991-997.
    PubMed     Abstract available

  27. LEMINI R, Jorgensen MS, Attwood K, Almerey T, et al
    Racial Disparities in Outcomes Among Asians With Gastric Cancer in the USA.
    Anticancer Res. 2020;40:881-889.
    PubMed     Abstract available

  28. FU CK, Chien YC, Chuang HY, Wang YC, et al
    The Association of MMP7 Promoter Polymorphisms With Gastric Cancer.
    Anticancer Res. 2020;40:695-702.
    PubMed     Abstract available

  29. AURELLO P, Cinquepalmi M, Petrucciani N, Moschetta G, et al
    Impact of Anastomotic Leakage on Overall and Disease-free Survival After Surgery for Gastric Carcinoma: A Systematic Review.
    Anticancer Res. 2020;40:619-624.
    PubMed     Abstract available

  30. BAUMGARTNER R, Taghizadeh H, Jomrich G, Schoppmann SF, et al
    Utilization and Efficacy of Palliative Chemotherapy for Locally Advanced or Metastatic Gastroesophageal Carcinoma.
    Anticancer Res. 2020;40:965-975.
    PubMed     Abstract available

    January 2020
  31. TAMAGAWA H, Aoyama T, Kano K, Numata M, et al
    The Impact of Intraoperative Blood Loss on the Long-term Prognosis after Curative Resection for Borrmann Type IV Gastric Cancer: A Retrospective Multicenter Study.
    Anticancer Res. 2020;40:405-412.
    PubMed     Abstract available

  32. YOO HJ, Kim TJ, Kim DJ, Kim W, et al
    Role of COX2 as a Biomarker for Estimating Survival of Patients With Clinical Stage I Gastric Cancer.
    Anticancer Res. 2020;40:341-347.
    PubMed     Abstract available

  33. ISHIKAWA D, Yoshikawa K, Takasu C, Kashihara H, et al
    Expression Level of MicroRNA-449a Predicts the Prognosis of Patients With Gastric Cancer.
    Anticancer Res. 2020;40:239-244.
    PubMed     Abstract available

  34. TAKANO Y, Shida A, Fujisaki M, Mitsumori N, et al
    Prognostic Significance of ZKSCAN3 (ZNF306) Expression in Gastric Carcinoma.
    Anticancer Res. 2020;40:81-86.
    PubMed     Abstract available

  35. KIJIMA T, Arigami T, Uenosono Y, Hiraki T, et al
    Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer.
    Anticancer Res. 2020;40:75-80.
    PubMed     Abstract available

    December 2019
  36. BAEK JH, Park DJ, Kim GY, Cheon J, et al
    Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
    Anticancer Res. 2019;39:6973-6979.
    PubMed     Abstract available

  37. KOSUGA T, Konishi T, Kubota T, Shoda K, et al
    Value of Prognostic Nutritional Index as a Predictor of Lymph Node Metastasis in Gastric Cancer.
    Anticancer Res. 2019;39:6843-6849.
    PubMed     Abstract available

  38. YAMAMOTO Y, Kuroda K, Sera T, Sugimoto A, et al
    The Clinicopathological Significance of the CXCR2 Ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in Gastric Cancer.
    Anticancer Res. 2019;39:6645-6652.
    PubMed     Abstract available

  39. ONEYAMA M, Sakamoto N, Oue N, Kimura Y, et al
    Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy.
    Anticancer Res. 2019;39:6567-6573.
    PubMed     Abstract available

  40. KIM JS, Bae GE, Kim KH, Lee SI, et al
    Prognostic Significance of LC3B and p62/SQSTM1 Expression in Gastric Adenocarcinoma.
    Anticancer Res. 2019;39:6711-6722.
    PubMed     Abstract available

    November 2019
  41. NAEEM B, Ayub A
    Primary Pediatric Non-Hodgkin Lymphomas of the Gastrointestinal Tract: A Population-based Analysis.
    Anticancer Res. 2019;39:6413-6416.
    PubMed     Abstract available

  42. TAKAHASHI Y, Fukuyama T, Futawatari N, Ichiki Y, et al
    Expression of Kita-Kyushu Lung Cancer Antigen-1 as Detected by a Novel Monoclonal Antibody in Gastric Cancer.
    Anticancer Res. 2019;39:6259-6263.
    PubMed     Abstract available

  43. ENDO S, Nishikawa K, Fujitani K, Matsuyama J, et al
    Is D2 Lymphadenectomy Essential for Cytology-positive Gastric Cancer? A Retrospective Analysis.
    Anticancer Res. 2019;39:6209-6216.
    PubMed     Abstract available

  44. SAWAKI K, Kanda M, Umeda S, Miwa T, et al
    Level of Melanotransferrin in Tissue and Sera Serves as a Prognostic Marker of Gastric Cancer.
    Anticancer Res. 2019;39:6125-6133.
    PubMed     Abstract available

  45. NAKATA S, Fujita M, Nakanishi H
    Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells.
    Anticancer Res. 2019;39:5927-5932.
    PubMed     Abstract available

  46. ENDO M, Kanda M, Sawaki K, Shimizu D, et al
    Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer.
    Anticancer Res. 2019;39:5903-5910.
    PubMed     Abstract available

  47. KHING TM, Po WW, Sohn UD
    Fluoxetine Enhances Anti-tumor Activity of Paclitaxel in Gastric Adenocarcinoma Cells by Triggering Apoptosis and Necroptosis.
    Anticancer Res. 2019;39:6155-6163.
    PubMed     Abstract available

    October 2019
  48. YU JI, Lim DH, Lee J, Kang WK, et al
    Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (</=45 Years) With Gastric Cancer.
    Anticancer Res. 2019;39:5811-5820.
    PubMed     Abstract available

  49. HASHIMOTO I, Sakamaki K, Oue N, Kimura Y, et al
    Clinical Significance of PRKCI Gene Expression in Cancerous Tissue in Patients With Gastric Cancer.
    Anticancer Res. 2019;39:5715-5720.
    PubMed     Abstract available

  50. TSAI KW, Tsai CY, Chou NH, Wang KC, et al
    Aberrant DNA Hypermethylation Silenced LncRNA Expression in Gastric Cancer.
    Anticancer Res. 2019;39:5381-5391.
    PubMed     Abstract available

    September 2019
  51. ANDO K, Hamada K, Watanabe M, Ohkuma R, et al
    Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors.
    Anticancer Res. 2019;39:5195-5201.
    PubMed     Abstract available

  52. NISHIMURA S, Yashiro M, Sera T, Yamamoto Y, et al
    Feasibility of Identifying Patients at High Risk of Hereditary Gastric Cancer Based on Clinicopathological Variables.
    Anticancer Res. 2019;39:5057-5064.
    PubMed     Abstract available

  53. KUBOTA T, Ichikawa D, Kosuga T, Shoda K, et al
    Does Robotic Distal Gastrectomy Facilitate Minimally Invasive Surgery for Gastric Cancer?
    Anticancer Res. 2019;39:5033-5038.
    PubMed     Abstract available

  54. ITO A, Nakanishi H, Yoshimura M, Ito S, et al
    Dynamics of Circulating Tumor Cells Early After Targeting Therapy to Human EGFR-mutated Lung Cancers and HER2 Gene-amplified Gastric Cancers in Mice.
    Anticancer Res. 2019;39:4711-4720.
    PubMed     Abstract available

  55. WOLL E, Eisterer W, Gerger A, Kuhr T, et al
    Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy.
    Anticancer Res. 2019;39:4589-4596.
    PubMed     Abstract available

    August 2019
  56. YAMAMOTO K, Hirao M, Nishikawa K, Omori T, et al
    Sarcopenia Is Associated With Impaired Overall Survival After Gastrectomy for Elderly Gastric Cancer.
    Anticancer Res. 2019;39:4297-4303.
    PubMed     Abstract available

  57. NAKAZAWA N, Ogata K, Yokobori T, Ide M, et al
    Low IRBIT Levels Are Associated With Chemo-resistance in Gastric Cancer Patients.
    Anticancer Res. 2019;39:4111-4116.
    PubMed     Abstract available

  58. VIRGILIO E, Giarnieri E, Montagnini M, Villani S, et al
    Advances in Intraluminal Exfoliative Cytology of Gastric Cancer: Oncologic Implication of the Sixth Metastatic Route (Metastasis VI).
    Anticancer Res. 2019;39:4019-4022.
    PubMed     Abstract available

  59. KANG BW, Baek DW, Kang H, Baek JH, et al
    Novel Therapeutic Approaches for Epstein-Barr Virus Associated Gastric Cancer.
    Anticancer Res. 2019;39:4003-4010.
    PubMed     Abstract available

    June 2019
  60. HIRAHARA N, Tajima Y, Fujii Y, Kaji S, et al
    Comprehensive Analysis of Red Blood Cell Distribution Width as a Preoperative Prognostic Predictor in Gastric Cancer.
    Anticancer Res. 2019;39:3121-3130.
    PubMed     Abstract available

  61. SATO Y, Inokuchi M, Takagi Y, Kojima K, et al
    IGFBP1 Is a Predictive Factor for Haematogenous Metastasis in Patients With Gastric Cancer.
    Anticancer Res. 2019;39:2829-2837.
    PubMed     Abstract available

  62. TAKI T, Hoya Y, Nakada K, Kawamura M, et al
    Gastric Emptying Improved Significantly After PRG Compared to Billroth-I Reconstruction: Assessment of Gastric Emptying With a (13)C-Breath Test.
    Anticancer Res. 2019;39:3227-3230.
    PubMed     Abstract available

    May 2019
  63. MURAKAMI Y, Saito H, Shimizu S, Kono Y, et al
    Neutrophil-to-Lymphocyte Ratio as a Prognostic Indicator in Patients With Unresectable Gastric Cancer.
    Anticancer Res. 2019;39:2583-2589.
    PubMed     Abstract available

  64. MATSUBARA D, Konishi H, Kubota T, Kosuga T, et al
    Comparison of Clinical Outcomes of Gastrojejunal Bypass and Gastrectomy in Patients With Metastatic Gastric Cancer.
    Anticancer Res. 2019;39:2545-2551.
    PubMed     Abstract available

  65. KUWADA K, Kuroda S, Kikuchi S, Yoshida R, et al
    Clinical Impact of Sarcopenia on Gastric Cancer.
    Anticancer Res. 2019;39:2241-2249.
    PubMed     Abstract available

    April 2019
  66. YOSHIDA Y, Beppu T, Kinoshita K, Sato N, et al
    Five-year Recurrence-free Survival After Surgery Followed by Oral Chemotherapy for Gastric Cancer With Portal Vein Tumor Thrombosis.
    Anticancer Res. 2019;39:2233-2238.
    PubMed     Abstract available

  67. SEO AN, Kang BW, Bae HI, Kwon OK, et al
    Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer.
    Anticancer Res. 2019;39:2145-2154.
    PubMed     Abstract available

  68. LIU JB, Jian T, Yue C, Chen D, et al
    Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus.
    Anticancer Res. 2019;39:1689-1698.
    PubMed     Abstract available

  69. AURELLO P, Berardi G, Moschetta G, Cinquepalmi M, et al
    Recurrence Following Anastomotic Leakage After Surgery for Carcinoma of the Distal Esophagus and Gastroesophageal Junction: A Systematic Review.
    Anticancer Res. 2019;39:1651-1660.
    PubMed     Abstract available

    March 2019
  70. SAITO R, Kawaguchi Y, Akaike H, Shiraishi K, et al
    Prognostic Significance of Lymph Node Dissection Along the Upper-third-stomach in Patients With Lower-third Gastric Cancer.
    Anticancer Res. 2019;39:1485-1489.
    PubMed     Abstract available

  71. NAKAJI YU, Saeki H, Kudou K, Nakanishi R, et al
    Short- and Long-term Outcomes of Surgical Treatment for Remnant Gastric Cancer After Distal Gastrectomy.
    Anticancer Res. 2019;39:1411-1415.
    PubMed     Abstract available

    February 2019
  72. AOYAMA T, Yoshikawa T, Maezawa Y, Segami K, et al
    Influence of Postoperative Surgical Complications After Gastrectomy on Body Weight and Body Composition Changes in Patients With Gastric Cancer.
    Anticancer Res. 2019;39:1073-1078.
    PubMed     Abstract available

  73. ENDO S, Kurokawa Y, Gamoh M, Kimura Y, et al
    Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202.
    Anticancer Res. 2019;39:1059-1065.
    PubMed     Abstract available

  74. VIRGILIO E, Giarnieri E, Giovagnoli MR, Montagnini M, et al
    Gastric Lavage Malignant Cells (yGL) and Hypohemoglobinemia (yAnemia) as New Systems of Tumor Regression Grading and Prognostic Prediction for Gastric Cancer After Neoadjuvant Treatment.
    Anticancer Res. 2019;39:1019-1027.
    PubMed     Abstract available

  75. TAMURA T, Sakurai K, Nambara M, Miki Y, et al
    Adverse Effects of Preoperative Sarcopenia on Postoperative Complications of Patients With Gastric Cancer.
    Anticancer Res. 2019;39:987-992.
    PubMed     Abstract available

  76. ELTWERI AM, Thomas AL, Chung WY, Morgan B, et al
    The Effect of Supplementary Omegaven(R) on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial.
    Anticancer Res. 2019;39:853-861.
    PubMed     Abstract available

    January 2019
  77. SAITO H, Shimizu S, Kono Y, Murakami Y, et al
    PD-1 Expression on Circulating CD8(+) T-Cells as a Prognostic Marker for Patients With Gastric Cancer.
    Anticancer Res. 2019;39:443-448.
    PubMed     Abstract available

  78. NUMAKURA S, Uozaki H, Kikuchi Y, Watabe S, et al
    Mesenchymal Stem Cell Marker Expression in Gastric Cancer Stroma.
    Anticancer Res. 2019;39:387-393.
    PubMed     Abstract available

  79. BAE GE, Kim HS, Won KY, Kim GY, et al
    Lower Sympathetic Nervous System Density and beta-adrenoreceptor Expression Are Involved in Gastric Cancer Progression.
    Anticancer Res. 2019;39:231-236.
    PubMed     Abstract available

  80. KIM DJ, Kim W
    Lower Esophageal Sphincter-preserving Anastomosis Is an Acceptable Reconstruction Method Following Laparoscopy-assisted Proximal Gastrectomy.
    Anticancer Res. 2019;39:425-430.
    PubMed     Abstract available

    December 2018
  81. SATO S, Kunisaki C, Tanaka Y, Sato K, et al
    A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer.
    Anticancer Res. 2018;38:6911-6917.
    PubMed     Abstract available

  82. MOCHIZUKI K, Kawai M, Odate T, Tahara I, et al
    SMARCB1/INI1 Is Diagnostically Useful in Distinguishing alpha-Fetoprotein-producing Gastric Carcinoma from Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:6865-6868.
    PubMed     Abstract available

  83. GIATROMANOLAKI A, Koukourakis MI, Georgiou I, Kouroupi M, et al
    LC3A, LC3B and Beclin-1 Expression in Gastric Cancer.
    Anticancer Res. 2018;38:6827-6833.
    PubMed     Abstract available

  84. YANG W, Cai J, Zhang H, Wang G, et al
    Effects of Lidocaine and Ropivacaine on Gastric Cancer Cells Through Down-regulation of ERK1/2 Phosphorylation In Vitro.
    Anticancer Res. 2018;38:6729-6735.
    PubMed     Abstract available

  85. LARBRE V, Alyami M, Mercier F, Vantard N, et al
    No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis.
    Anticancer Res. 2018;38:6869-6875.
    PubMed     Abstract available

    November 2018
  86. LUCCHETTI J, Formica V, Giuliano G, Coletta D, et al
    Case Report of a Patient with Breast Metastasis from Gastric Cancer Treated with Paclitaxel and Ramucirumab Plus Regional Hyperthermia.
    Anticancer Res. 2018;38:6561-6564.
    PubMed     Abstract available

  87. FUKUCHI M, Mochiki E, Ishiguro T, Kumagai Y, et al
    Prognostic Significance of Conversion Surgery Following First- or Second-line Chemotherapy for Unresectable Gastric Cancer.
    Anticancer Res. 2018;38:6473-6478.
    PubMed     Abstract available

  88. DE FATIMA FERREIRA BORGES DA C, DE Castro Sant' Anna C, Muniz JAPC, DA Rocha CAM, et al
    Deregulation of the SRC Family Tyrosine Kinases in Gastric Carcinogenesis in Non-human Primates.
    Anticancer Res. 2018;38:6317-6320.
    PubMed     Abstract available

  89. SEKINO N, Kano M, Matsumoto Y, Sakata H, et al
    The Antitumor Effects of Metformin on Gastric Cancer In Vitro and on Peritoneal Metastasis.
    Anticancer Res. 2018;38:6263-6269.
    PubMed     Abstract available

  90. KIM HM, Jeong I, Kim HJ, Kang SK, et al
    Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
    Anticancer Res. 2018;38:6171-6180.
    PubMed     Abstract available

  91. MIYOSHI S, Tsugawa H, Matsuzaki J, Hirata K, et al
    Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
    Anticancer Res. 2018;38:6163-6170.
    PubMed     Abstract available

  92. UETA K, Otowa Y, Kakeji Y, Hirashima M, et al
    PROX1 Is Associated with Cancer Progression and Prognosis in Gastric Cancer.
    Anticancer Res. 2018;38:6139-6145.
    PubMed     Abstract available

  93. KAWAKUBO E, Matsumoto T, Yoshiya K, Yamashita S, et al
    BUBR1 Insufficiency Is Correlated with eNOS Reduction Experimentally In Vitro and In Vivo, and in Gastric Cancer Tissue.
    Anticancer Res. 2018;38:6099-6106.
    PubMed     Abstract available

    October 2018
  94. TANAKA Y, Kunisaki C, Izumisawa Y, Makino H, et al
    A Phase I/II Study of NAC with Docetaxel, Cisplatin, and S-1 for Stage III Gastric Cancer.
    Anticancer Res. 2018;38:6015-6021.
    PubMed     Abstract available

  95. SHINKAI M, Imano M, Chiba Y, Hiraki Y, et al
    Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
    Anticancer Res. 2018;38:5975-5981.
    PubMed     Abstract available

  96. SHINKAI M, Imano M, Chiba Y, Hiraki Y, et al
    Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
    Anticancer Res. 2018;38:5969-5974.
    PubMed     Abstract available

  97. SUGIYAMA K, Narita Y, Mitani S, Honda K, et al
    Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer.
    Anticancer Res. 2018;38:5859-5866.
    PubMed     Abstract available

  98. GONZALEZ-HORMAZABAL P, Romero S, Musleh M, Bustamante M, et al
    IL-8-251T>A (rs4073) Polymorphism Is Associated with Prognosis in Gastric Cancer Patients.
    Anticancer Res. 2018;38:5703-5708.
    PubMed     Abstract available

  99. VIRGILIO E, Ceci D, Cavallini M
    Surgical Endoscopic Vacuum-assisted Closure Therapy (EVAC) in Treating Anastomotic Leakages After Major Resective Surgery of Esophageal and Gastric Cancer.
    Anticancer Res. 2018;38:5581-5587.
    PubMed     Abstract available

  100. ATHAUDA A, Watkins D, Mohammed K, Chau I, et al
    Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
    Anticancer Res. 2018;38:5943-5949.
    PubMed     Abstract available

  101. ISHIGAMI S, Aridome K, Arigami T, Uenosono Y, et al
    Roux-en-Y Plus Distal Jejunal Pouch After Total Gastrectomy: A Prospective Study.
    Anticancer Res. 2018;38:5837-5841.
    PubMed     Abstract available

  102. PARK R, Williamson S, Kasi A, Saeed A, et al
    Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer.
    Anticancer Res. 2018;38:5569-5580.
    PubMed     Abstract available

    September 2018
  103. KOMATSU S, Kosuga T, Kubota T, Okamoto K, et al
    Preoperative Low Weight Affects Long-term Outcomes Following Curative Gastrectomy for Gastric Cancer.
    Anticancer Res. 2018;38:5331-5337.
    PubMed     Abstract available

  104. ISHIDA R, Kanaji S, Maehara R, Hasegawa H, et al
    Significance of Additional Gastrectomy Including Endoscopic Submucosal Dissection Scar for Gastric Cancer.
    Anticancer Res. 2018;38:5289-5294.
    PubMed     Abstract available

    August 2018
  105. HIRAHARA N, Tajima Y, Fujii Y, Yamamoto T, et al
    Preoperative Prognostic Nutritional Index Predicts Long-term Outcome in Gastric Cancer: A Propensity Score-matched Analysis.
    Anticancer Res. 2018;38:4735-4746.
    PubMed     Abstract available

  106. HOWARD R, Al Diffalha S, Pimiento J, Mejia J, et al
    CD133 Expression as a Helicobacter pylori-independent Biomarker of Gastric Cancer Progression.
    Anticancer Res. 2018;38:4443-4448.
    PubMed     Abstract available

  107. KASHIHARA H, Shimada M, Yoshikawa K, Higashijima J, et al
    The Effect of Roux-en-Y Reconstruction on Type 2 Diabetes in the Early Postoperative Period.
    Anticancer Res. 2018;38:4901-4905.
    PubMed     Abstract available

    July 2018
  108. ROMERO S, Musleh M, Bustamante M, Stambuk J, et al
    Polymorphisms in TWIST1 and ZEB1 Are Associated with Prognosis of Gastric Cancer Patients.
    Anticancer Res. 2018;38:3871-3877.
    PubMed     Abstract available

    June 2018
  109. TANAKA H, Tamura T, Toyokawa T, Muguruma K, et al
    Clinical Relevance of Postoperative Neutrophil-Lymphocyte Ratio (NLR) to Recurrence After Adjuvant Chemotherapy of S-1 for Gastric Cancer.
    Anticancer Res. 2018;38:3745-3751.
    PubMed     Abstract available

  110. OBERMANNOVA R, Redova-Lojova M, Vychytilova-Faltejskova P, Grell P, et al
    Tumor Expression of miR-10b, miR-21, miR-143 and miR-145 Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population.
    Anticancer Res. 2018;38:3719-3724.
    PubMed     Abstract available

  111. MARANO L, Rondelli F, Bartoli A, Testini M, et al
    Oncologic Effectiveness and Safety of Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: Meta-analysis of Randomized Controlled Trials.
    Anticancer Res. 2018;38:3609-3617.
    PubMed     Abstract available

  112. NISHI M, Yoshikawa K, Higashijima J, Tokunaga T, et al
    The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer.
    Anticancer Res. 2018;38:3387-3392.
    PubMed     Abstract available

  113. CHOU NH, Lo YH, Wang KC, Kang CH, et al
    MiR-193a-5p and -3p Play a Distinct Role in Gastric Cancer: miR-193a-3p Suppresses Gastric Cancer Cell Growth by Targeting ETS1 and CCND1.
    Anticancer Res. 2018;38:3309-3318.
    PubMed     Abstract available

  114. BOLM L, Kasmann L, Paysen A, Karapetis C, et al
    Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer.
    Anticancer Res. 2018;38:3231-3242.
    PubMed     Abstract available

  115. CHUNG T, DO SI, Na K, Kim G, et al
    Stromal p16 Overexpression in Gastric-type Mucinous Carcinoma of the Uterine Cervix.
    Anticancer Res. 2018;38:3551-3558.
    PubMed     Abstract available

    May 2018
  116. HWANG GY, Baek DW, Cho HJ, Lee SJ, et al
    Elevated Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy.
    Anticancer Res. 2018;38:3151-3156.
    PubMed     Abstract available

  117. KIUCHI J, Komatsu S, Kosuga T, Kubota T, et al
    Long-term Postoperative Nutritional Status Affects Prognosis Even After Infectious Complications in Gastric Cancer.
    Anticancer Res. 2018;38:3133-3138.
    PubMed     Abstract available

  118. IWABU J, Namikawa T, Tsuda S, Kitagawa H, et al
    Successful Distal Gastrectomy for Gastric Cancer with Child-Pugh Class B Alcoholic Liver Cirrhosis.
    Anticancer Res. 2018;38:3085-3087.
    PubMed     Abstract available

  119. MARUYAMA S, Furuya S, Shiraishi K, Shimizu H, et al
    Podoplanin Expression as a Prognostic Factor in Gastric Cancer.
    Anticancer Res. 2018;38:2717-2722.
    PubMed     Abstract available

  120. MONDLANE G, Ureba A, Gubanski M, Lind PA, et al
    Estimation of Risk of Normal-tissue Toxicity Following Gastric Cancer Radiotherapy with Photon- or Scanned Proton-beams.
    Anticancer Res. 2018;38:2619-2625.
    PubMed     Abstract available

    April 2018
  121. OTOWA Y, Suzuki S, Kanaji S, Harada H, et al
    Curative Gastrectomy with Perioperative Chemotherapy Improves the Survival for Unresectable Gastric Cancer.
    Anticancer Res. 2018;38:2363-2368.
    PubMed     Abstract available

  122. HARUTA Y, Nakanishi R, Jogo T, Nakashima Y, et al
    Gastric Cancer of "Crawling Type" Detected by Additional Gastrectomy After Endoscopic Submucosal Resection.
    Anticancer Res. 2018;38:2335-2338.
    PubMed     Abstract available

  123. VIRGILIO E, Balducci G, Mercantini P, Giarnieri E, et al
    Laparoscopic Intragastric Surgery for Treating Early Gastric Cancer.
    Anticancer Res. 2018;38:1911-1916.
    PubMed     Abstract available

  124. CHIU YM, Tsai CL, Kao JT, Hsieh CT, et al
    PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma.
    Anticancer Res. 2018;38:2069-2078.
    PubMed     Abstract available

  125. TSAI CL, Chiu YM, Ho TY, Hsieh CT, et al
    Gallic Acid Induces Apoptosis in Human Gastric Adenocarcinoma Cells.
    Anticancer Res. 2018;38:2057-2067.
    PubMed     Abstract available

    March 2018
  126. ARATANI K, Sakuramoto S, Chuman M, Kasuya M, et al
    Laparoscopy-assisted Distal Gastrectomy for Gastric Cancer in Elderly Patients: Surgical Outcomes and Prognosis.
    Anticancer Res. 2018;38:1721-1725.
    PubMed     Abstract available

  127. INOKUCHI M, Nakagawa M, Baogok N, Takagi Y, et al
    Prognostic Significance of High EphA1-4 Expression Levels in Locally Advanced Gastric Cancer.
    Anticancer Res. 2018;38:1685-1693.
    PubMed     Abstract available

  128. IGUCHI K, Kunisaki C, Sato S, Tanaka Y, et al
    Evaluation of Optimal Lymph Node Dissection in Remnant Gastric Cancer Based on Initial Distal Gastrectomy.
    Anticancer Res. 2018;38:1677-1683.
    PubMed     Abstract available

  129. KINOSHITA K, Beppu T, Miyata T, Kuramoto K, et al
    A Case of 15-Year Recurrence-free Survival After Microwave Coagulation Therapy for Liver Metastasis from Gastric Cancer.
    Anticancer Res. 2018;38:1595-1598.
    PubMed     Abstract available

  130. HONMA R, Sakamoto N, Ishikawa A, Taniyama D, et al
    Clinicopathological and Prognostic Significance of Epithelial Gremlin1 Expression in Gastric Cancer.
    Anticancer Res. 2018;38:1419-1425.
    PubMed     Abstract available

  131. VIRGILIO E, Giarnieri E, Giovagnoli MR, Montagnini M, et al
    Gastric Cancer Cells in Peritoneal Lavage Fluid: A Systematic Review Comparing Cytological with Molecular Detection for Diagnosis of Peritoneal Metastases and Prediction of Peritoneal Recurrences.
    Anticancer Res. 2018;38:1255-1262.
    PubMed     Abstract available

    February 2018
  132. PALAJ J, Keckes S, Marek V, Dyttert D, et al
    Fibrinogen Levels Are Associated with Lymph Node Involvement and Overall Survival in Gastric Cancer Patients.
    Anticancer Res. 2018;38:1097-1104.
    PubMed     Abstract available

  133. NAKAMURA A, Matsunaga W, Gotoh A
    Autophagy Induced by Naftopidil Inhibits Apoptosis of Human Gastric Cancer Cells.
    Anticancer Res. 2018;38:803-809.
    PubMed     Abstract available

  134. VIRGILIO E, Giarnieri E, Giovagnoli MR, Montagnini M, et al
    Gastric Juice MicroRNAs as Potential Biomarkers for Screening Gastric Cancer: A Systematic Review.
    Anticancer Res. 2018;38:613-616.
    PubMed     Abstract available

  135. CEAUSU AR, Ciolofan A, Cimpean AM, Magheti A, et al
    The Mesenchymal-Epithelial and Epithelial-Mesenchymal Cellular Plasticity of Liver Metastases with Digestive Origin.
    Anticancer Res. 2018;38:811-816.
    PubMed     Abstract available

    January 2018
  136. VIRGILIO E, Balducci G, Mercantini P, Giarnieri E, et al
    Utility of Nasogastric Tube for Medical and Surgical Oncology of Gastric Cancer: A Prospective Institutional Study on a New and Precious Application of an Old and Economic Device.
    Anticancer Res. 2018;38:433-439.
    PubMed     Abstract available

  137. SHIN SH, Park SS, Ju EJ, Park J, et al
    Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer.
    Anticancer Res. 2018;38:287-293.
    PubMed     Abstract available

  138. SAITO H, Kono Y, Murakami Y, Shishido Y, et al
    Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.
    Anticancer Res. 2018;38:107-112.
    PubMed     Abstract available

  139. DOMINGUEZ C, Rosa M, George TB, Pimiento J, et al
    Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
    Anticancer Res. 2018;38:367-372.
    PubMed     Abstract available

    December 2017
  140. MASUISHI T, Kadowaki S, Kondo M, Komori A, et al
    FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis.
    Anticancer Res. 2017;37:7037-7042.
    PubMed     Abstract available

  141. FUJII H, Iihara H, Kajikawa N, Kobayashi R, et al
    Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy.
    Anticancer Res. 2017;37:6831-6837.
    PubMed     Abstract available

  142. INOKUCHI M, Higuchi K, Takagi Y, Tanioka T, et al
    Cadherin 5 Is a Significant Risk Factor for Hematogenous Recurrence and a Prognostic Factor in Locally Advanced Gastric Cancer.
    Anticancer Res. 2017;37:6807-6813.
    PubMed     Abstract available

  143. NISHI M, Batsaikhan BE, Yoshikawa K, Higashijima J, et al
    High STAT4 Expression Indicates Better Disease-free Survival in Patients with Gastric Cancer.
    Anticancer Res. 2017;37:6723-6729.
    PubMed     Abstract available

  144. ANDREOU A, Pesthy S, Struecker B, Dadras M, et al
    Incidence and Risk Factors of Symptomatic Hiatal Hernia Following Resection for Gastric and Esophageal Cancer.
    Anticancer Res. 2017;37:7031-7036.
    PubMed     Abstract available

    November 2017
  145. KANAZAWA Y, Yamada T, Fujita I, Kakinuma D, et al
    In Vitro Chemosensitivity Test for Gastric Cancer Specimens Predicts Effectiveness of Oxaliplatin and 5-Fluorouracil.
    Anticancer Res. 2017;37:6401-6405.
    PubMed     Abstract available

    October 2017
  146. VIRGILIO E, Balducci G, Mercantini P, Ferri M, et al
    Reconstruction After Distal Gastrectomy for Gastric Cancer: Billroth 2 or Roux-En-Y Procedure?
    Anticancer Res. 2017;37:5595-5602.
    PubMed     Abstract available

  147. WOLL E, Thaler J, Keil F, Gruenberger B, et al
    Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.
    Anticancer Res. 2017;37:5553-5558.
    PubMed     Abstract available

  148. LEE AA, Poddar N, Hammami MB, Veerapong J, et al
    Gastric Spindle Cell Neuroendocrine Tumor Mimicking Gastrointestinal Stromal Tumor: Unique Morphology and Diagnostic Pitfall.
    Anticancer Res. 2017;37:5893-5897.
    PubMed     Abstract available

    September 2017
  149. PACHNIA D, Drop B, Dworzanska A, Kliszczewska E, et al
    Transforming Growth Factor-beta, Interleukin-10, and Serological Markers in EBV-associated Gastric Carcinoma.
    Anticancer Res. 2017;37:4853-4858.
    PubMed     Abstract available

    August 2017
  150. YIN J, Song JN, Bai ZG, Cai J, et al
    Gastric Cancer Mortality Trends in China (2006-2013) Reveal Increasing Mortality in Young Subjects.
    Anticancer Res. 2017;37:4671-4679.
    PubMed     Abstract available

  151. DONG W, Li B, Wang J, Song Y, et al
    Exploration of the Radiotherapeutic Clinical Target Volume Delineation for Gastric Cancer from Lymph Node Metastases.
    Anticancer Res. 2017;37:4629-4634.
    PubMed     Abstract available

  152. HUO X, Xiao X, Zhang S, Zhou D, et al
    Association of Intron Microsatellite Instability and Exon Mutational Profile of TP53 in Human Gastric Cancers.
    Anticancer Res. 2017;37:4507-4514.
    PubMed     Abstract available

  153. YIN J, Cui Y, Li L, Ji J, et al
    Overexpression of EPHB4 Is Associated with Poor Survival of Patients with Gastric Cancer.
    Anticancer Res. 2017;37:4489-4497.
    PubMed     Abstract available

  154. LI L, Cui Y, Ji JF, Jiang WG, et al
    Clinical Correlation Between WISP2 and beta-Catenin in Gastric Cancer.
    Anticancer Res. 2017;37:4469-4473.
    PubMed     Abstract available

  155. JIANG A, Zhao H, Liu X, Yu M, et al
    Comparison of Different Muscle-Relaxant Anesthetics on Growth, Migration and Invasion of Gastric Cancer Cells.
    Anticancer Res. 2017;37:4371-4378.
    PubMed     Abstract available

  156. MIMATSU K, Fukino N, Ogasawara Y, Saino Y, et al
    Utility of Inflammatory Marker- and Nutritional Status-based Prognostic Factors for Predicting the Prognosis of Stage IV Gastric Cancer Patients Undergoing Non-curative Surgery.
    Anticancer Res. 2017;37:4215-4222.
    PubMed     Abstract available

  157. VIRGILIO E, Giarnieri E, Giovagnoli MR, Montagnini M, et al
    Early Gastric Cancer Exfoliating into Gastric Lavage (GL1 EGC) Shows a More Aggressive Behavior and Poorer Survival Compared to the Non-Exfoliative Counterpart (GL0 EGC).
    Anticancer Res. 2017;37:4199-4203.
    PubMed     Abstract available

  158. LIU L, Zhao H, Sheng L, Yang P, et al
    Collision of Lymphoepithelioma-like Carcinoma with Diffuse Large B-cell Lymphoma of the Stomach: A Case Report.
    Anticancer Res. 2017;37:4569-4573.
    PubMed     Abstract available

  159. GONG Z, Mu Y, Chen J, Chu H, et al
    Expression and Significance of Cyclophilin J in Primary Gastric Adenocarcinoma.
    Anticancer Res. 2017;37:4475-4481.
    PubMed     Abstract available

    July 2017
  160. TAKIMOTO R, Kamigaki T, Okada S, Matsuda E, et al
    Efficacy of Adoptive Immune-cell Therapy in Patients with Advanced Gastric Cancer: A Retrospective Study.
    Anticancer Res. 2017;37:3947-3954.
    PubMed     Abstract available

  161. SATAKE H, Kondo M, Mizumoto M, Kotake T, et al
    Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer.
    Anticancer Res. 2017;37:3703-3710.
    PubMed     Abstract available

  162. KAITO A, Kinoshita T, Tokunaga M, Sunagawa H, et al
    Prognostic Factors and Recurrence Pattern of Far-advanced Gastric Cancer with Pathologically-positive Para-aortic Lymph Nodes.
    Anticancer Res. 2017;37:3685-3692.
    PubMed     Abstract available

  163. KASHIHARA H, Shimada M, Yoshikawa K, Higashijima J, et al
    Correlation Between Thrombospondin-1 Expression in Non-cancer Tissue and Gastric Carcinogenesis.
    Anticancer Res. 2017;37:3547-3552.
    PubMed     Abstract available

    June 2017
  164. MOON JH, Fujiwara Y, Hirao M, Imamura H, et al
    Randomized Controlled Trial of Adjuvant Chemotherapy with Fluoropyrimidines Versus Surgery-alone for Gastric Cancer.
    Anticancer Res. 2017;37:3061-3067.
    PubMed     Abstract available

  165. TOKUMOTO M, Tanaka H, Tauchi Y, Tamura T, et al
    Immunoregulatory Function of Lymphatic Endothelial Cells in Tumor-draining Lymph Nodes of Human Gastric Cancer.
    Anticancer Res. 2017;37:2875-2883.
    PubMed     Abstract available

  166. VIRGILIO E, Proietti A, D'Urso R, Cardelli P, et al
    Measuring Intragastric Tumor Markers in Gastric Cancer Patients: a Systematic Literature Review on Significance and Reliability.
    Anticancer Res. 2017;37:2817-2821.
    PubMed     Abstract available

  167. ARATANI K, Komatsu S, Ichikawa D, Ohashi T, et al
    Overexpression of EGFR as an Independent Prognostic Factor in Adenocarcinoma of the Esophagogastric Junction.
    Anticancer Res. 2017;37:3129-3135.
    PubMed     Abstract available

    May 2017
  168. KANAZAWA Y, Fujita I, Kakinuma D, Arai H, et al
    Initial Experience with Nab-Paclitaxel for Patients with Advanced Gastric Cancer: Safety and Efficacy.
    Anticancer Res. 2017;37:2715-2720.
    PubMed     Abstract available

  169. INADOMI K, Kusaba H, Matsushita Y, Tanaka R, et al
    Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer.
    Anticancer Res. 2017;37:2663-2671.
    PubMed     Abstract available

  170. DA SILVA OLIVEIRA KC, Bona AB, DA Silva FJ, Pinheiro TM, et al
    Expression of hsa-miR-9 and MYC Copy Number Variation in Hereditary Diffuse Gastric Cancer.
    Anticancer Res. 2017;37:2401-2406.
    PubMed     Abstract available

    April 2017
  171. TAHARA T, Tahara S, Horiguchi N, Kawamura T, et al
    Telomere Length in Leukocyte DNA in Gastric Cancer Patients and its Association with Clinicopathological Features and Prognosis.
    Anticancer Res. 2017;37:1997-2001.
    PubMed     Abstract available

  172. KUNIZAKI M, Fukuda A, Wakata K, Tominaga T, et al
    Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
    Anticancer Res. 2017;37:1979-1984.
    PubMed     Abstract available

    March 2017
  173. FUKUCHI M, Mochiki E, Ishiguro T, Ogura T, et al
    Efficacy of Conversion Surgery Following S-1 plus Cisplatin or Oxaliplatin Chemotherapy for Unresectable Gastric Cancer.
    Anticancer Res. 2017;37:1343-1347.
    PubMed     Abstract available

  174. MITA K, Ito H, Ota E, Takahashi K, et al
    Adjuvant Chemotherapy with S-1 plus Cisplatin for Patients with Stage III Gastric Cancer After Curative Resection.
    Anticancer Res. 2017;37:1329-1333.
    PubMed     Abstract available

  175. AHN SY, Kim J, Kim MA, Choi J, et al
    Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
    Anticancer Res. 2017;37:1127-1138.
    PubMed     Abstract available

  176. DAI X, Liu D, Liu M, Zhang X, et al
    Anti-metastatic Efficacy of Traditional Chinese Medicine (TCM) Ginsenoside Conjugated to a VEFGR-3 Antibody on Human Gastric Cancer in an Orthotopic Mouse Model.
    Anticancer Res. 2017;37:979-986.
    PubMed     Abstract available

    February 2017
  177. SATOH T, Kaira K, Takahashi K, Takahashi N, et al
    Prognostic Significance of the Expression of CD98 (4F2hc) in Gastric Cancer.
    Anticancer Res. 2017;37:631-636.
    PubMed     Abstract available

  178. BAUER G
    Central Signaling Elements of Intercellular Reactive Oxygen/Nitrogen Species-dependent Induction of Apoptosis in Malignant Cells.
    Anticancer Res. 2017;37:499-513.
    PubMed     Abstract available

  179. BACKMAN S, Norlen O, Eriksson B, Skogseid B, et al
    Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
    Anticancer Res. 2017;37:705-712.
    PubMed     Abstract available

  180. PROUET P, Giri S, Wiedower E, Fintel A, et al
    Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality.
    Anticancer Res. 2017;37:813-817.
    PubMed     Abstract available

    January 2017
  181. OGATA K, Yanai M, Kuriyama K, Suzuki M, et al
    Double Endoscopic Intraluminal Operation (DEILO) for Early Gastric Cancer: Outcome of Novel Procedure for Endoscopic Submucosal Dissection.
    Anticancer Res. 2017;37:343-347.
    PubMed     Abstract available

  182. SUGIYAMA K, Narita Y, Kadowaki S, Ura T, et al
    Platinum-based Doublet Chemotherapy for Advanced Gastric Cancer with Disseminated Intravascular Coagulation.
    Anticancer Res. 2017;37:309-313.
    PubMed     Abstract available

  183. JUKIC Z, Radulovic P, Stojkovic R, Mijic A, et al
    Gender Difference in Distribution of Estrogen and Androgen Receptors in Intestinal-type Gastric Cancer.
    Anticancer Res. 2017;37:197-202.
    PubMed     Abstract available

  184. KOGURE N, Yokobori T, Ogata K, Altan B, et al
    Low Expression of FBXO45 Is Associated with Gastric Cancer Progression and Poor Prognosis.
    Anticancer Res. 2017;37:191-196.
    PubMed     Abstract available

  185. LEE D, Yu EJ, Ham IH, Hur H, et al
    Clinicopathological Implication of Insulin-like Growth Factor-II mRNA-Binding Protein 3 (IMP3) Expression in Gastric Cancer.
    Anticancer Res. 2017;37:135-142.
    PubMed     Abstract available

    December 2016
  186. FUKUCHI M, Mochiki E, Ishiguro T, Ogura T, et al
    Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer.
    Anticancer Res. 2016;36:6699-6703.
    PubMed     Abstract available

  187. TOIYAMA Y, Shimura T, Yasuda H, Fujikawa H, et al
    Clinical Burden of C-Reactive Protein/Albumin Ratio Before Curative Surgery for Patients with Gastric Cancer.
    Anticancer Res. 2016;36:6491-6498.
    PubMed     Abstract available

    November 2016
  188. ZHENG LC, Yang MD, Kuo CL, Lin CH, et al
    Norcantharidin-induced Apoptosis of AGS Human Gastric Cancer Cells Through Reactive Oxygen Species Production, and Caspase- and Mitochondria-dependent Signaling Pathways.
    Anticancer Res. 2016;36:6031-6042.
    PubMed     Abstract available

  189. HAYASHI N, Kataoka H, Yano S, Kikuchi JI, et al
    Anticancer Effects of a New Aminosugar-conjugated Platinum Complex Agent Against Cisplatin-resistant Gastric Cancer.
    Anticancer Res. 2016;36:6005-6009.
    PubMed     Abstract available

    October 2016
  190. ARIGAMI T, Uenosono Y, Ishigami S, Yanagita S, et al
    Clinical Impact of Stomach-partitioning Gastrojejunostomy with Braun Enteroenterostomy for Patients with Gastric Outlet Obstruction Caused by Unresectable Gastric Cancer.
    Anticancer Res. 2016;36:5431-5436.
    PubMed     Abstract available

  191. ALTAN B, Yokobori T, Ide M, Bai T, et al
    High Expression of MRE11-RAD50-NBS1 Is Associated with Poor Prognosis and Chemoresistance in Gastric Cancer.
    Anticancer Res. 2016;36:5237-5247.
    PubMed     Abstract available

  192. YAWATA K, Osada S, Tanahashi T, Matsui S, et al
    The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.
    Anticancer Res. 2016;36:5215-5226.
    PubMed     Abstract available

  193. LEMOINE N, Adenis A, Bouche O, Duhamel A, et al
    Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma.
    Anticancer Res. 2016;36:5543-5549.
    PubMed     Abstract available

  194. KNIEF J, Reddemann K, Petrova E, Herhahn T, et al
    High Density of Tumor-infiltrating B-Lymphocytes and Plasma Cells Signifies Prolonged Overall Survival in Adenocarcinoma of the Esophagogastric Junction.
    Anticancer Res. 2016;36:5339-5345.
    PubMed     Abstract available

    September 2016
  195. KIM EY, Jun KH, Jung JH, Jo YS, et al
    Laparoscopic Gastrectomy Followed by Chemotherapy for Advanced Gastric Cancer Diagnosed During Pregnancy: A Case Report.
    Anticancer Res. 2016;36:4813-6.
    PubMed     Abstract available

  196. KIM DJ, Kim W
    Laparoscopy-assisted Proximal Gastrectomy with Double Tract Anastomosis Is Beneficial for Vitamin B12 and Iron Absorption.
    Anticancer Res. 2016;36:4753-8.
    PubMed     Abstract available

    August 2016
  197. ROMAN LD, Lukyanchuk R, Sablin OA, Araslanova EI, et al
    Prevalence of H. pylori Infection and Atrophic Gastritis in a Population-based Screening with Serum Biomarker Panel (GastroPanel(R)) in St. Petersburg.
    Anticancer Res. 2016;36:4129-38.
    PubMed     Abstract available

    June 2016
  198. KOMATSU S, Ichikawa D, Kosuga T, Okamoto K, et al
    Clinical Impact of Laparoscopy and Endoscopy Cooperative Surgery (LECS) on Gastric Submucosal Tumor After its Standardization.
    Anticancer Res. 2016;36:3041-7.
    PubMed     Abstract available

  199. YONENAGA Y, Kurosawa M, Mise M, Yamagishi M, et al
    Pancreatic-type Acinar Cell Carcinoma of the Stomach Included in Multiple Primary Carcinomas.
    Anticancer Res. 2016;36:2855-64.
    PubMed     Abstract available

    March 2016
  200. ZIMMERMANN N, Lazar-Karsten P, Keck T, Billmann F, et al
    Expression Pattern of CDX2, Estrogen and Progesterone Receptors in Primary Gastroenteropancreatic Neuroendocrine Tumors and Metastases.
    Anticancer Res. 2016;36:921-4.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.